Health grants for Small business

Expected Impact: The action under this topic is expected to achieve the following impacts and contribute to the following EU policies/initiatives: deliver innovative, early technology solutions that contribute to addressing strategic unmet public health needs across multiple therapy areas to improve prevention, early diagnosis, and treatment; leverage the unique network and scale of IHI JU members to create a pipeline to support innovative startups in the health industry, fully integrated into European initiatives in support of start-ups and entrepreneurship; drive early cross-sector health R&D and innovation to strengthen the European healthcare industry’s global competitiveness, contributing to the EU Industrial Strategy and Pharmaceutical Strategy objectives; create a sustainable network of European healthcare incubators to guide and support highly talented and innovative early-stage companies; harness digital health and data-sharing technologies (e.g., AI and big data) to enable interoperable health solutions, contributing to the European Health Data Space (EHDS) and improved evidence based care;- the action should generate a portfolio of early‑stage companies that have…

Expected Outcome: Project results are expected to contribute to all of the following expected outcomes: land managers, farmers, foresters, agri-businesses (including SMEs), and policy makers gain access to practical knowledge of clear demonstrations of benefits and trade-offs associated with biologically diversifying their agroecosystem; farmers, land managers and foresters are incentivised and rewarded for implementing practices that improve agrobiodiversity, leading to higher incomes and long-term sustainability and resilience of agriculture, greater food security, competitiveness, and healthier ecosystems; enhanced capabilities for farmers to store, process, and market their diverse raw materials and products, derived from greater agrobiodiversity, while improving their market access and strengthening their position within the value chain. Scope: Genetic erosion poses a significant threat to agricultural resilience, as genetic diversity is crucial for crops to withstand environmental stresses such as climate variations, pests, and diseases. As the global population grows, the demand for increased food production often drives large-scale agriculture, which compromises…

Expected Impact: The developed solutions should demonstrate their potential in concrete terms through the execution of a first roll-out stage during the project life-cycle, with a strong uptake strategy guiding their future adoption after the end of the project. The sustainability of the results and their continued benefits to users is a key ambition of this call for proposals. The project is furthermore expected to make a strong impact for the wider ecosystem of European decentralised social media. The insights gained on youth needs and desires on mental-health and inclusivity friendly social media should benefit the wider community of stakeholders in this space, and wherever possible developed technology should contribute to the software stacks of the ActivityPub and ATProtocol communities. Finally, the project should generate insights on the opportunities and challenges for decentralised social media as a genuine and widely used alternative to non-decentralised services, and contribute to the understanding of the key factors that would allow EU tech start-ups in the space to scale and succeed. Through the specific focus on youth audiences, the project may also provide use cases…

The purpose of this Notice of Funding Opportunity (NOFO) is to leverage NICHD clinical research Network infrastructure relevant to infants, children, women, pregnant and lactating women, and persons with disabilities to conduct innovative, multisite, investigator-initiated clinical trials and observational studies. This NOFO will utilize a bi-phasic (UG3/UH3), milestone-driven mechanism consisting of a start-up phase (UG3) and a full enrollment and clinical trial implementation phase (UH3). Applications submitted in response to this NOFO must address specific aims and milestones for both the UG3 and UH3 phases. A UG3 project (phase I) that meets its milestones will be administratively considered by NICHD and prioritized for transition to the UH3 award (phase II). This NOFO provides an opportunity to leverage NICHD clinical research Network infrastructure as a platform for investigator-initiated innovative hypotheses by any investigator in the extramural community. Applications must be submitted as investigator-initiated, multi-Project Director/Principal Investigator (PD/PI) grant applications in conjunction with the respective NICHD-supported Network Data Coordinating Center (DCC), or equivalent as determined by the NICHD.

This funding opportunity announcement (FOA) encourages grant applications that support the activities of the National Primate Research Centers (NPRCs). Nonhuman primates (NHPs) are most closely related to humans, both physiologically and genetically. Therefore, NHPs are critical animal models for basic and translational research aimed at understanding human biology, both in normal and diseased states. Proper husbandry and management of NHPs require specialized physical and intellectual resources, which are most effectively and economically provided in centralized primate centers, the resources of which are made available to investigators on a national basis. The NPRCs provide these resources to investigators/grantees who utilize NHPs in biomedical research and thereby complement and help enable the missions of the NIH Institutes and Centers.

The purpose of this Notice of Funding Opportunity (NOFO) is to solicit applications for the conduct of scientific research utilizing data from expanded access (EA) for investigational drugs or biological products as described in section 561 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360bbb). These applications will target intermediate size populations of patients living with amyotrophic lateral sclerosis (ALS) who are not eligible for ongoing clinical trials for the prevention, diagnosis, mitigation, treatment, or cure of ALS.

Expected Impact: FOR ALL THREE THEMATIC PRIORITIES: Expected impact at the closure of the project (non-exhaustive list): Innovative technologies tested and adopted by the market; Innovative solutions deployed improving businesses confidence, competences and means to digitalise and grow; Contribution to digitisation and health systems transformation, through various types of innovation and the supply of IT services; Uptake of technologically/economically reliable and viable solutions on the market; Deployment of new technologies fostering the growth of Europe’s manufacturing sector; Innovative technologies adopted by SMEs; Identification of possible sources of funding/funding mix, to cover the residual investment needs (public-private partnerships for the deployment of innovation, the collaboration with venture capitals, EIB group loans etc); Strengthening innovation diffusion channels; Reinforcing the capacity of regions to co-invest together, joining forces on common S3 investment priorities (interregional investments). Long-term impact (non-exhaustive list): Increased companies’ productivity and efficiency; Improved user-friendly, accessible and interoperable public…

Expected Impact: FOR ALL THREE THEMATIC PRIORITIES: Expected impact at the closure of the project (non-exhaustive list): Creation of new value chains in less developed regions and transition regions; Application and deployment of innovative technologies and solutions (new to the region) in less developed and transition regions (innovation diffusion); Exploitation of project results; Innovative technologies tested and adopted by the market; Innovative solutions deployed improving businesses confidence, competences and means to digitalise and grow; Contribution to digitisation and health systems transformation, through various types of innovation and the supply of IT services; Uptake of technologically/economically reliable and viable solutions on the market; Deployment of new technologies fostering the growth of Europe’s manufacturing sector; Innovative technologies adopted by SMEs; Identification of possible sources of funding/funding mix, to cover the residual investment needs (public-private partnerships for the deployment of innovation, the collaboration with venture capitals, EIB group loans etc); Strengthening innovation diffusion channels; Reinforcing the capacity of regions…

The objective of this funding opportunity is to support investigator-initiated, Phase I clinical trials for diagnostic and therapeutic interventions for heart, lung, blood, and sleep (HLBS) disorders in adults and children. In addition to supporting clinical trial start-up and implementation activities, this FOA will provide support for final stage preclinical activities needed for the implementation of the proposed trial. All the activities proposed in the R61 phase must be directly related to the therapeutic/diagnostic in preparation for the clinical trial. The proposed trial can be single or multisite. This NOFO will utilize a bi-phasic, milestone-driven mechanism of award where the first phase can be used to finalize required pre-trial activities such as stability, shipping studies, and site training.

The Small Business Technology Transfer (STTR) grant program helps United States small business concerns (SBCs) that partner with a nonprofit research institution bring scientific innovations to the marketplace. The STTR program supports feasibility studies to later stage research and development (R&D) needed to develop a commercial product.

The Small Business Innovation Research (SBIR) program helps United States small business concerns (SBCs) bring scientific innovations to the marketplace. The SBIR program supports feasibility studies to later research and development (R&D) needed to develop a commercial product.

The NIH Phase IIB Strategic Breakthrough award bridges the funding gap between the end of a Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) Phase II award and commercialization. The Phase IIB Strategic Breakthrough provides previously funded NIH SBIR or STTR projects additional support for later-stage research and development (R&D).

The Institutional Development Awards (IDeA) program supports biomedical research capacity building in states that have historically received low levels of NIH funding. The Centers of Biomedical Research Excellence: Development Phase (COBRE-D) program supports institutions in IDeA states to increase their biomedical research capacity in a broad scientific area of strategic importance to them but for which they have limited existing infrastructure or expertise.COBRE-D supports a long-term institutional vision focused on the recruitment and mentoring of early-career investigators with supplemental start-up packages for new hires, the establishment of research facilities, and enhancement of research administration support services. This program serves as an on-ramp for less-resourced institutions to the Centers of Biomedical Research Excellence: Expansion/Sustainability Phases (COBRE-E/S) program. This is a Notice of Funding Opportunity (NOFO) for a Limited Competition that will invite application(s) from eligible organization(s) to apply. Please see Section III. Eligibility for additional information. In accordance with NIH standard peer-review processes, the application(s) will be peer-reviewed, and only meritorious application(s) will be considered.

The Commercialization Readiness Pilot (CRP) program helps small business concerns (SBCs) move NIH-funded SBIR or STTR projects from late-stage development to commercialization. The CRP supports later-stage research and development (R&D) and/or technical assistance that Phase II and Phase IIB Strategic Breakthrough awards do not typically support. This includes:Independent replication or confirmation of key studiesIND- or IDE-enabling studiesClinical studiesManufacturing scale-up and related quality activitiesRegulatory and other specialized technical supportSBCs may subcontract (outsource) a significant amount of the work in a CRP to meet the project goals.